Trial Investigating Pembrolizumab for Hormone-Sensitive Prostate Cancer Discontinued
Merck has decided to end the phase 3 KEYNOTE-991 trial due to futility.
Diagnosis & Disease Information
Discrimination Tied to Frailty in African-American Cancer Survivors
Among African-American cancer survivors, experiencing discrimination is associated with frailty, a study suggests.
Metastasis-Directed Therapy Protective in Recurrent Prostate Cancer
New findings could have implications for the use of salvage therapies.
Surgery, Radiation Therapy Offer Similar Survival in High-Risk Prostate Cancer
Investigators analyzed data from 3 randomized controlled trials and data from their own prospective institutional database.
Low Prostate Cancer-Specific Mortality Seen for Men With Localized Disease
New research suggests that men with localized prostate cancer have low prostate cancer-specific mortality at 15 years, regardless of the treatment they receive.
Prostate Cancer Treatment Pluvicto Currently in Shortage
Pluvicto is currently in shortage due to challenges in meeting demand and no therapeutic equivalents being available.
Increasing Use of Active Surveillance for Low-Risk Prostate Cancer
From 2014 to 2021, the rates of active surveillance for low-risk prostate cancer increased, but there was considerable variation in its use.
Novel Prostate Cancer Variants Identified in Men With African Ancestry
Of the 9 novel variants, 7 were only found or were more common in men of African ancestry.
Depth of PSA Decline Linked to Outcomes of Castration-Resistant Prostate Cancer
Greater depth of PSA decline is associated with improved outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide.
How Triplets and Doublets Compare in Metastatic Castration-Sensitive Prostate Cancer
A meta-analysis suggests that abiraterone-based triplet therapy may be best for high-volume mCSPC, and API-based doublet regimens may be best for low-volume mCSPC.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...